GeparNuevo DFS

# 506 Oral presentation: Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Loibl S, Schneeweiss A, Huober J, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 506)
Presentation

PENELOPE-B HTG

# 519 Poster discussion: Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.
Denkert C, Marmé F, Matrtin M, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 519)
Poster

PENELOPE-B premenopausal

# 518 Poster discussion: Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.
Marmé F, Martin M, Untch M, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 518)
Poster

BCP INCIP

# 515 Poster discussion: Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
Amant F, Nekljudova V, Maggen C, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 515)
Poster

SASCIA

# TPS602 Poster presentation: Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.
Marmé F, Stickeler E, Furlanetto J, et al. J Clin Oncol 39, 2021 (suppl 15; abstr TPS602)
Poster

External projects with GBG participation

ASCENT

# 1011Clinical Science Symposium: Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
Kalinsky K, Oliviera M, Traina TA, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 1011)

APHINITY

# 510 Poster discussion: Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.
De Azambuja E, Eiger D, Procter MJ, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 510)

HER2CLIMB

# 1043 Poster presentation: Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
Curligliano G, Mueller V, Borges VF, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 1043)

ASCENT

# 1080 Poster presentation: Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
Carey LA, Loirat D, Punie K, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 1080)

OlympiA

#LBA1 Oral presentation: OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.
Tutt A, Garber JE, Kaufman B . J Clin Oncol 39, 2021 (suppl 15; abstr LBA1)

• Visit the Conference website for more information